Welcome to our dedicated page for ZIMVIE news (Ticker: ZIMV), a resource for investors and traders seeking the latest updates and insights on ZIMVIE stock.
Overview of ZimVie Inc
ZimVie Inc is a global life sciences company intricately focused on the dental and spine markets. With a comprehensive portfolio that spans from dental implants to spinal fusion devices, ZimVie has established itself as a key player in advancing both clinical science and technological innovation in these segments. Utilizing cutting-edge digital workflow solutions, such as its RealGUIDE® software suite, the company integrates precise digital planning with state-of-the-art product design to support predictable outcomes in implant dentistry and spinal surgeries.
Dental Products Segment
The dental arm of ZimVie is dedicated to developing and manufacturing a wide range of products that support tooth replacement and restorative procedures. This segment includes dental implants, premium restorative components, and advanced digital care management solutions. ZimVie has emphasized innovation through products like TSX and T3 PRO implants which incorporate proprietary surface technologies designed to maintain crestal bone levels and support long-term peri-implant health. Complementing these hardware solutions is the GenTek restorative portfolio that enhances the dental implant system through digitally driven CAD/CAM restorative workflows. Such integration of robust biomaterials with intelligent design tools has positioned the company at the forefront of modern implant dentistry.
Spine Products Segment
On the spine side, ZimVie extends its expertise to devices that are critical in spinal fusion surgeries and related procedures. The spine products segment comprises implants, surgical instruments, bone graft substitutes, and non-fusion alternatives designed to address a range of spinal conditions. By focusing on precision engineering and advanced surgical technology, ZimVie provides solutions that contribute to improved surgical outcomes and enhanced patient recovery. The company's approach in both the dental and spine markets underlines its commitment to innovation and quality within the broader medical device industry.
Innovation and Digital Workflow Integration
At the core of ZimVie’s strategy is the commitment to technological integration. The company has developed advanced digital workflows that empower clinicians to plan, design, and implement surgical procedures with enhanced accuracy. The RealGUIDE® Dental Implant Software Suite, for example, offers features such as one-click nerve detection and automated segmentation, significantly reducing procedural risk and streamlining case planning. This integration of digital tools with traditional implant procedures not only improves efficiency but also bolsters the clinical reliability of ZimVie’s products.
Operational Excellence and Market Position
ZimVie consistently emphasizes a systematic approach to research and development, manufacturing, and market deployment. By organizing its business into two streamlined segments—dental and spine—the company efficiently addresses the evolving needs in both areas while maintaining stringent quality standards. The incorporation of digital planning supports scalable, end-to-end solutions that enhance both clinical outcomes and operational efficiency. ZimVie’s rigorous focus on optimizing the interface between implants and restorative components, paired with its commitment to digital advancement, reinforces its market significance and operational resilience.
Industry Terminology and Expertise
Key industry-specific terms such as CAD/CAM integration, biomaterials, and implant surface technology are central to understanding ZimVie’s technical expertise. The company’s dual focus on physical device innovation and digital workflow advancements positions it uniquely within the competitive landscape of healthcare solutions. By leveraging precise engineering and innovative digital tools, ZimVie supports clinicians in delivering therapies that are both aesthetically pleasing and functionally robust.
Commitment to Quality and Clinical Outcomes
Quality assurance and patient safety are embedded in every aspect of ZimVie’s business model. The company’s products are developed with a clear focus on long-term clinical benefits, establishing a balance between immediate surgical needs and enduring oral and spinal health. Through continuous improvement initiatives and strict adherence to industry standards, ZimVie has built a reputation for delivering products that meet critical health and safety benchmarks.
ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management team will deliver a presentation on Tuesday, April 8, 2025 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time.
Investors and interested parties can access the live webcast and archived recording of the presentation through ZimVie's investor website at investor.zimvie.com.
ZimVie (Nasdaq: ZIMV), a global dental implant market leader, announced key changes to its Board of Directors. David King, Non-Executive Chair, will not seek reelection when his term expires at the May 7, 2025 shareholders meeting.
Current President and CEO Vafa Jamali will assume the role of Chairman of the Board, while Director Vinit Asar will become Lead Independent Director. Asar, a board member since 2022, currently chairs the Quality, Regulatory, and Technology Committee and serves on the Audit, Corporate Governance, and Compensation Committees.
Under Jamali's leadership since the company's spinoff, ZimVie has transformed into a focused dental company, reduced debt to enhance financial flexibility, and streamlined operations. Asar also serves as Executive Chairman of Hanger, Inc.
ZimVie (NASDAQ: ZIMV) reported its Q4 and FY2024 financial results, marking a transformational year as a pure-play dental company. Full-year 2024 third-party net sales reached $449.7 million, down 1.6% from 2023, with a net loss of $(33.8) million. The company achieved an Adjusted EBITDA of $60.0 million with a 13.3% margin.
In Q4 2024, third-party net sales were $111.5 million, decreasing 1.4% year-over-year, with a net loss of $(9.7) million. However, this represented a $12.5 million improvement from Q4 2023's loss. The quarter's Adjusted EBITDA reached $18.4 million, with a 16.5% margin, showing a 420 basis points increase.
Notable achievements include reducing net debt by over $290 million, streamlining operations through corporate cost reduction, and implementing manufacturing efficiency initiatives. Despite softer end markets, the company improved its Adjusted EBITDA margins by over 4 percentage points in Q4 2024 compared to Q4 2023.
ZimVie Inc (Nasdaq: ZIMV), a global life sciences leader in the dental market, has announced it will release its fourth quarter and full-year 2024 financial results after market close on Wednesday, February 26, 2025. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Interested participants are advised to register online more than 15 minutes before the call begins. A replay of the webcast will be made available on the company's investor relations website.
ZimVie Inc. (NASDAQ: ZIMV) announced the publication of a scientific study in the Journal of Biomedical Materials Research demonstrating the advantages of their dental implant surface technology. The study compared ZimVie's T3® PRO and TSX® Implants' dual acid-etched coronal surface technology with other leading implant brands.
The research identified a critical threshold roughness for dental implants, below which bacterial adhesion remains similar to smooth machined surfaces. ZimVie's implants' coronal surfaces, DAE and Osseotite®, are engineered around this threshold, showing bacterial adhesion levels comparable to machined surfaces while maintaining crestal bone levels similar to rougher surfaces.
The findings suggest that ZimVie's implants may help reduce the risk of peri-implant infections compared to other commercial implants, addressing the growing concern of peri-implant mucositis and peri-implantitis in dental implantology.
ZimVie Inc. (ZIMV) reported Q3 2024 financial results with third-party net sales of $103.2 million, showing a 2.0% decrease from Q3 2023. The company posted a net loss of $(3.0) million, improving from a $(10.2) million loss in the previous year. Adjusted EBITDA reached $13.1 million with a 12.7% margin, up 110 basis points year-over-year. The company reported GAAP diluted EPS of $(0.11) and adjusted diluted EPS of $0.12. ZimVie updated its full-year 2024 guidance, projecting net sales between $450M to $455M and adjusted EBITDA between $60M to $62M.
ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, has announced its participation in the upcoming UBS Global Healthcare Conference. The company's management will deliver a presentation on Tuesday, November 12, 2024, at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time.
Interested parties can access both the live webcast and an archived recording of the presentation through ZimVie's investor website at investor.zimvie.com.
ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, has announced that it will report its third quarter 2024 financial results after market close on Wednesday, October 30, 2024. The company will host a conference call to discuss the results, beginning at 4:30 p.m. Eastern Time on the same day.
Interested parties can register for the conference call online. It is recommended to register more than 15 minutes before the call starts. For those unable to attend the live call, a replay of the webcast will be made available on the company's investor relations website at investor.zimvie.com.
ZimVie Inc. (ZIMV) reported Q2 2024 financial results for its continuing operations in the dental market. Key highlights include:
- Third party net sales of $116.8 million, down 1.5% year-over-year
- Net loss of $(9.6) million, with a net loss margin of 8.2%
- Adjusted EBITDA of $16.1 million, with a 13.8% margin
- Reduced debt to $235.1 million
- Cash balance of $78.6 million
The company reaffirmed its full-year 2024 guidance, projecting net sales of $450-$460 million, adjusted EBITDA of $60-$65 million, and adjusted EPS of $0.55-$0.70. CEO Vafa Jamali highlighted progress in customer engagement, product innovation, and operational improvements.
ZimVie Inc. (Nasdaq: ZIMV) has released RealGUIDE® 5.4, an update to its dental implant software suite. This latest version introduces new features designed to enhance provider efficiency and cost savings. Key improvements include:
1. One-click nerve detection and automated bone and tooth segmentation for faster complex case planning and improved risk management.
2. New restorative design workflows to meet evolving clinic and dental laboratory needs.
3. Amplified CAD workflows for creating attractive implant dentistry designs.
4. Automated 'split-bar' toolset for efficient creation of complex multi-material prostheses.
5. Cloud-based design libraries for improved accessibility.
The update aims to make guided surgery the standard for all implant cases, potentially increasing implant dentistry adoption.
FAQ
What is the current stock price of ZIMVIE (ZIMV)?
What is the market cap of ZIMVIE (ZIMV)?
What are ZimVie Inc's core business segments?
How does ZimVie integrate digital technology into its product offerings?
What innovations distinguish ZimVie’s dental implant solutions?
How does ZimVie address the needs of the spine market?
What role does digital planning play in ZimVie’s product strategy?
How does ZimVie ensure quality and safety in its products?
What is the significance of ZimVie’s GenTek restorative portfolio?
How does ZimVie differentiate itself from competitors in its field?
